Structures cardiac rehab prescriptions with exercise parameters and risk stratification. Use when prescribing cardiac rehab, setting exercise targets, or monitoring rehab progress.
Structures cardiac rehab prescriptions with exercise parameters and risk stratification.
Cardiac rehabilitation reduces cardiovascular mortality by 20–30% and all-cause mortality by 13–24%, yet fewer than 25% of eligible patients are referred or enrolled. CMS expanded coverage in 2024 to include heart failure (HFrEF) as a qualifying diagnosis, and the AHA/AACVPR recognize cardiac rehab as a Class I recommendation for post-MI, post-CABG, post-PCI, stable angina, heart failure, and post-valve surgery patients.
The exercise prescription in cardiac rehabilitation must be individualized based on risk stratification, functional capacity, comorbidities, and hemodynamic response to exercise. A poorly calibrated prescription risks either undertreating a patient capable of higher workloads or triggering ischemia/arrhythmia in a high-risk patient.
AHA/AACVPR Risk Stratification:
| Risk Level | Criteria | Monitoring Level |
|---|---|---|
| Low | Uncomplicated MI/PCI, LVEF ≥ 50%, no ischemia on stress test, no complex arrhythmia, functional capacity ≥ 7 METs | ECG monitoring initial sessions → discontinue when stable |
| Moderate | LVEF 40–49%, or mild residual ischemia, or functional capacity 5–6.9 METs, or inability to self-monitor | Continuous ECG monitoring × 6–12 sessions |
| High | LVEF < 40%, complex ventricular arrhythmia, exercise-induced ischemia at low workload (< 5 METs), hemodynamic instability | Continuous ECG monitoring throughout program, physician-supervised sessions |
Absolute Contraindications to Exercise:
Frequency: 3–5 sessions per week (minimum 36 sessions over 12–18 weeks per CMS coverage)
Intensity Prescription Methods:
| Method | Calculation | Best For |
|---|---|---|
| HR reserve (Karvonen) | THR = [(HRmax − HRrest) × %intensity] + HRrest | Most accurate; requires max HR from stress test |
| % of HRmax | THR = HRmax × %intensity | When stress test available |
| RPE (Borg 6–20 scale) | Target: 11–14 ("fairly light" to "somewhat hard") | When HR unreliable (AFib, paced rhythm, beta-blocker) |
| METs method | Target: 40–80% of peak METs from stress test | When precise MET data available |
| Talk test | Able to speak in sentences but not sing | Supplementary; useful for patient self-monitoring |
Starting Intensity (by risk level):
Time: 20–60 minutes of aerobic exercise per session (start at 15–20 for deconditioned patients, progress by 5 min/week)
Type:
Session Monitoring Checklist:
Progression Protocol:
Core Components Beyond Exercise:
| Component | Target/Action |
|---|---|
| Blood pressure | < 130/80 mmHg; medication optimization |
| Lipids | LDL < 70 mg/dL (< 55 if very high risk); high-intensity statin |
| Diabetes | HbA1c < 7% (individualized); SGLT2i if HF |
| Smoking | Absolute cessation; pharmacotherapy (varenicline, NRT, bupropion) |
| Weight | BMI < 30 kg/m²; waist circumference targets |
| Psychosocial | Screen for depression (PHQ-9), anxiety; refer for counseling |
| Nutrition | Mediterranean or DASH diet; sodium < 2 g/day for HF; referral to dietitian |
Outcome Metrics to Track:
Phase Progression:
Transition Plan for Phase III: